Direct Medical Costs of Incident Complications in Patients Newly Diagnosed With Type 2 Diabetes in China

Abstract

Introduction Reliable country-specific incidence and cost data on diabetes-related complications are essential inputs for the projections of the economic burden of diabetes. The aim of this study was to provide patient-level cost estimates of managing and treating complications in patients newly diagnosed with type 2 diabetes mellitus (T2DM) in China. Methods Patients newly diagnosed with T2DM in the Tianjin Urban Employee Basic Medical Insurance Claims database between 2008 and 2015 were identified and followed up. The cumulative incidence and descriptive costs of certain macrovascular and microvascular complications were examined. A generalized estimating equations model was used to estimate the immediate- and long-term costs for the incident complication in quarterly intervals, controlling for demographics and the confounding effects of comorbid complications. Results A total of 114,847 newly diagnosed patients were identified (mean age 56.9 years, 45.5% women). After 7 years, 80.8% of the patients at risk had developed nephropathy and 75.7% had developed neuropathy. The immediate additional costs were highest for myocardial infarction during the quarterly interval that the complication first occurred (China yuan [CNY] 19,633), and the long-term costs were highest for stroke in the quarterly intervals of subsequent years (CNY 1087). The expected costs for all complications were calculated and presented as costs per quarterly interval and per year for different age and sex subgroups. Conclusions Managing complications results in substantial costs to the Chinese healthcare system. Our study contributes towards quantifying the economic burden and supports the parametrization of economic models of diabetes in China. Electronic supplementary material The online version of this article (10.1007/s13300-020-00967-y) contains supplementary material, which is available to authorized users.

Healthcare resource utilization in patients treated with empagliflozin in East Asia

“…This patient population is expected to increase to approximately 212 million by 2045 1 . Type 2 diabetes generally imposes a substantial burden on healthcare systems globally as it results in a high demand for healthcare resources and high associated costs [1][2][3][4] , and East Asia is no exception [5][6][7][8][9][10][11][12][13] . Hospital inpatient care is the largest component of medical expenditure in type 2 diabetes, with one study estimating that hospitalization accounted for 43% of total medical costs 14 .…”

Potential health and economic impact associated with achieving risk factor control in Chinese adults with diabetes: a microsimulation modelling study

“…For complications that were not reported by Duan et al., we used estimates derived from urban populations reported by He et al. for neuropathy and retinopathy, 26 and Wang et al. for amputation.…”

Obesity vs. Metabolically Healthy Obesity in East Asia

“…A recent survey of heart failure alone in China estimated a mean per-capita cost of USD 4407 for inpatients, and a 2012 estimation reported that heart failure total costs were USD 5.42 billion, indicating a severe burden on a country where even a 1.10% estimated prevalence translates into millions of patients [52,57]. A 2020 study on the direct costs of diabetes in management and subsequent heart, cerebral, and vascular diseases reported costs of USD 109 billion in 2019, increased care costs of up to USD 2847 per person during care for the first myocardial infarction, and a peak cost age range from 70 to 80 years old [58]. For obesity, a scoping meta-analysis of the time period from 2010-2020 found direct medical costs of between USD 8.4 and 23.9 billion but with additional indirect costs (facility, supply, record keeping, etc.)…”